Skip to content

Topical Rosemary Oil Application in Systemic Sclerosis

Psychophysiological Effect of Local Rosemary and Olive Oil Application Onto the Hands of Patients With Systemic Sclerosis - a Prospective Crossover, Open-label, Nonrandomized Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03531216
Enrollment
12
Registered
2018-05-21
Start date
2015-11-02
Completion date
2016-03-21
Last updated
2019-01-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Systemic Sclerosis

Brief summary

The objectives of this prospective crossover, open-label, nonrandomized study are to estimate effect sizes of vasodilatation and sense of warmth after application of topical rosemary essential oil in patients suffering from systemic sclerosis.

Detailed description

In a crossover design, patients suffering from systemic sclerosis (12 subjects) receive applications of olive oil and of 10% Rosmarinus officinalis L. (rosemary) essential oil to both hands with a wash-out period of 3 hours. Effects on vasodilatation are measured with infrared thermography. Patients' sense of warmth is assessed by the Herdecke warmth perception questionnaire. Measurements take place at baseline and 45 minutes following the interventions (pre-post-comparison). To determine within and between-differences, 2-sample t-tests will be used and effect sizes will be calculated (Standardized Effect Size).

Interventions

OTHERPlacebo

Topically-applied oil to both dorsal and palmar aspects of the hands

OTHERRosemary essential oil

Topically-applied oil to both dorsal and palmar aspects of the hands

Sponsors

University Hospital Tuebingen
CollaboratorOTHER
ARCIM Institute Academic Research in Complementary and Integrative Medicine
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Systemic sclerosis with skin involvement of hands and fingers * Raynaud phenomenon with frequent symptoms of cold hands

Exclusion criteria

* Topical treatment with nitroglyceride * Lymphdrainage \< 24 hours * Other topical treatment of hands and arms \< 4 hours prior to study intervention

Design outcomes

Primary

MeasureTime frameDescription
Change from baseline in temperature at the fingersbaseline and 45 minutes after the interventionDistal skin temperature in °C measured at the fingers with a high-definition infrared camera (FLIR-Systems, type SC660) before and 45 minutes following the oil application

Secondary

MeasureTime frameDescription
Change from baseline in temperature at the back of the handsbaseline and 45 minutes after the interventionDistal skin temperature in °C measured at the back of the hands with a high-definition infrared camera (FLIR-Systems, type SC660) before and 45 minutes following the oil application
Change from baseline in temperature at the forearmsbaseline and 45 minutes after the interventionDistal skin temperature in °C measured at the forearms with a high-definition infrared camera (FLIR-Systems, type SC660) before and 45 minutes following the oil application
Change from baseline of Herdecke warmth perception questionnaire (HeWEF)baseline and 45 minutes after the interventionPatients' sense of warmth in different body regions as well as overall warmth assessed before and 45 minutes following the oil application
Scleroderma Health Assessment Questionnaire (SHAQ)baselineQuestionnaire with 8 sections: e.g. dressing, arising, eating, walking,hygiene, etc... with 2 or 3 questions for each section. Scoring within each section is from0 (without any difficulty) to 3 (unable to do).
Rodnan skin score of the handsbaselineSkin score to assess the clinical severity of systemic scleroderma. 17 body areas are assessed by clinical palpation. The examiner assesses the skin thickness using a 4-point scale:0 = normal thickness, 1 = weak skin thickening, 2 = moderate skin thickening, 3 = severe skin thickening.

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026